LEUKERAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Leukeran, and when can generic versions of Leukeran launch?
Leukeran is a drug marketed by Waylis Therap and is included in one NDA.
The generic ingredient in LEUKERAN is chlorambucil. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the chlorambucil profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LEUKERAN?
- What are the global sales for LEUKERAN?
- What is Average Wholesale Price for LEUKERAN?
Summary for LEUKERAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 124 |
| Clinical Trials: | 6 |
| Patent Applications: | 3,961 |
| Drug Prices: | Drug price information for LEUKERAN |
| What excipients (inactive ingredients) are in LEUKERAN? | LEUKERAN excipients list |
| DailyMed Link: | LEUKERAN at DailyMed |
Recent Clinical Trials for LEUKERAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| TG Therapeutics, Inc. | Phase 3 |
| GlaxoSmithKline | Phase 3 |
| University of Liverpool | Phase 3 |
Pharmacology for LEUKERAN
| Drug Class | Alkylating Drug |
| Mechanism of Action | Alkylating Activity |
US Patents and Regulatory Information for LEUKERAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Waylis Therap | LEUKERAN | chlorambucil | TABLET;ORAL | 010669-002 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
